The Value of 68Ga-FAPI PET/CT in Detecting Recurrent and Metastatic Lesions in Patients with Thyroid Cancer After Surgery

Launched by RUIJIN HOSPITAL · Jan 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a special imaging test called 68Ga-FAPI PET/CT to see how well it can detect if thyroid cancer has come back or spread to other parts of the body after surgery. Researchers want to find out if this test can help doctors identify these issues more effectively in patients who have already had their thyroid cancer treated. The trial is currently looking for participants aged 18 to 80 who have had surgery for thyroid cancer and are suspected of having a recurrence or metastatic disease.

To join the study, participants need to sign a consent form and be willing to follow the research procedures. However, people with serious health conditions, such as severe heart or lung issues, or those who are pregnant or breastfeeding, cannot take part. If you decide to join, you can expect to undergo the 68Ga-FAPI PET/CT imaging test, which is a safe procedure designed to help improve the understanding and treatment of thyroid cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with thyroid cancer who have undergone surgery and are suspected of recurrence or metastasis during clinical evaluation.
• • 2. Signed and dated informed consent form.
• • 3. Commitment to comply with research procedures and co-operation in the implementation of the full research process.
• • 4. Aged 18-80 years old.
• Exclusion Criteria:
• • 1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
• • 2. Intestinal perforation, complete intestinal obstruction.
• • 3. Pregnant women and women who may be pregnant, women who are breastfeeding.
• • 4. Non-compliant person.